Lucie-Marie Scailteux

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 12

Top Venues

Fundamental & clinical pharmacology

British journal of clinical pharmacology

Cardiovascular drugs and therapy

BJU international

Université de Rennes 1 (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Université de Rennes 1

France

PHD :: Vie-Agro-Santé PhD school

Publications

Chabnam Yosofi, Sophie Cairon-Lejeune, Claudia Lefeuvre-Plesse, Elisabeth Polard, Marie Briet, Solène-Florence Kammerer-Jacquet, Louise Triquet, Lucie-Marie Scailteux
Osteonecrosis of the jaw under palbociclib: A case series description. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
François Boujonnier, Florian Lemaitre, Lucie-Marie Scailteux
Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information. Cardiovascular drugs and therapy (2023)
Pauline Berthe, Lucie-Marie Scailteux, Alexis Dechosal, Delphine Staumont, Guillaume Coiffier, Pierre Guéret, Alain Dupuy, Emmanuel Oger, Catherine Droitcourt
Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case-time control study and a nested case-control study based on the French national health insurance (SNDS) cohort. BMJ open 12 (9) (2022)
Lucie-Marie Scailteux, Valérian Capelle, Frédéric Balusson, Emmanuel Oger, Sébastien Vincendeau, Romain Mathieu, Anthony Chapron
Changes in prostate cancer screening practice by blood PSA testing between 2011 and 2017, a French population-based study. Current medical research and opinion 37 (8) (2021)
Lucie-Marie Scailteux, Fabien Despas, Frédéric Balusson, Boris Campillo-Gimenez, Romain Mathieu, Sébastien Vincendeau, André Happe, Emmanuel Nowak, Sandrine Kerbrat, Emmanuel Oger
Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: A French population-based study on prostate cancer patients. British journal of clinical pharmacology (2021)
Jacques Bouget, Frédéric Balusson, Maxime Maignan, Laure Pavageau, Pierre-Marie Roy, Karine Lacut, Lucie-Marie Scailteux, Emmanuel Nowak, Emmanuel Oger
Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study. British journal of clinical pharmacology 86 (12) (2020)
Viviane Kovess Masfety, Frédéric Balusson, Emmanuelle Leray, Mathilde Husky, Lucie-Marie Scailteux
Prescription patterns of first- and second-generation antipsychotic drugs in the French population. Fundamental & clinical pharmacology 34 (5) (2020)
Gincy George, Lucie-Marie Scailteux, Hans Garmo, Frédéric Balusson, Christopher Cardwell, Greet De Coster, Harlinde De Schutter, Josephina G Kuiper, Úna McMenamin, Julie Verbeeck, Mieke Van Hemelrijck
Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases. Fundamental & clinical pharmacology 33 (4) (2019)
Astrid Bacle, Charlotte Pronier, Helene Gilardi, Elisabeth Polard, Sophie Potin, Lucie-Marie Scailteux
Hepatotoxicity risk factors and acetaminophen dose adjustment, do prescribers give this issue adequate consideration? A French university hospital study. European journal of clinical pharmacology 75 (8) (2019)
Jacques Bouget, Frédéric Balusson, Lucie-Marie Scailteux, Maxime Maignan, Pierre-Marie Roy, Erwan L'her, Laure Pavageau, Emmanuel Nowak
Major bleeding with antithrombotic agents: a 2012-2015 study using the French nationwide Health Insurance database linked to emergency department records within five areas - rationale and design of SACHA study. Fundamental & clinical pharmacology 33 (4) (2019)
Lucie-Marie Scailteux, Nathalie Rioux-Leclercq, Sébastien Vincendeau, Frédéric Balusson, Emmanuel Nowak, Emmanuel Oger, null null
Use of 5α-reductase inhibitors for benign prostate hypertrophy and risk of high grade prostate cancer: a French population-based study. BJU international 123 (2) (2018)
Lucie-Marie Scailteux, Frédéric Balusson, Sébastien Vincendeau, Nathalie Rioux-Leclercq, Emmanuel Nowak
Rationale and design of the CANARI study: a case-control study investigating the association between prostate cancer and 5-alpha-reductase inhibitors for symptomatic benign prostate hypertrophy by linking SNIIRAM and pathology laboratories in a specific region in France. Fundamental & clinical pharmacology 32 (1) (2017)

Lucie-Marie Scailteux.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Lucie-Marie Scailteux